Correspondingly, Clobenpropit and Gemcitabine synergized to increase apoptosis in the mouse model, owing to the upregulation of E-cadherin and the downregulation of Zeb1. According to these findings, Clobenpropit, particularly when combined with Gemcitabine, shows efficacy at impeding tumor progression and inducing programmed cell death, suggesting that it may be a promising treatment for pancreatic cancer (Paik et al., 2014). The gene discussed is CDH1; the disease is neoplasm.